CD28 and neoplasm: As anti‐CD3/CD28 antibodies activated T cells cannot specifically target tumor cells in vitro without tumor antigen presentation during their development and maturation, chimeric antigen receptor T (CAR‐T) cells were used as a model for their specific antitumor abilities.